SCHEMBL5072207

SCHEMBL5072207

CCCCn1c(CN(Cc2ccc(C)cc2)Cc2cccc3ccccc23)cnc1-c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.39
PPARA Q07869 2/20 0.39
TSHR P16473 2/20 0.39
C5AR1 P21730 1/20 0.37
HSD11B1 P28845 2/20 0.36
CYP2C19 P33261 2/20 0.36
CYP2D6 P10635 2/20 0.34
NR1I2 O75469 1/20 0.34
LMNA P02545 1/20 0.34
ADRA2A P08913 1/20 0.34
ACHE P22303 1/20 0.34
SLC6A2 P23975 1/20 0.34
HTR2A P28223 1/20 0.34
SLC6A4 P31645 1/20 0.34
KCNH2 Q12809 1/20 0.34
SIGMAR1 Q99720 1/20 0.34
CYP1A2 P05177 1/20 0.33
NR1H3 Q13133 1/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5072389 0.95 TSHR (0.41) PPARGPPARATSHRC5AR1HSD11B1
SCHEMBL5137298 0.94 PPARG (0.39) PPARGPPARATSHRC5AR1HSD11B1
SCHEMBL5135150 0.94 HSD11B1 (0.40) PPARGPPARATSHRC5AR1HSD11B1
SCHEMBL5137554 0.93 MAPT (0.38) PPARGPPARATSHRC5AR1HSD11B1
SCHEMBL5134565 0.91 PPARG (0.42) PPARGPPARATSHRC5AR1LMNA
SCHEMBL5135533 0.91 PPARG (0.44) PPARGPPARATSHRC5AR1HSD11B1
SCHEMBL5136045 0.91 PPARG (0.37) PPARGPPARATSHRC5AR1HSD11B1
SCHEMBL5136060 0.91 CASR (0.40) PPARGPPARATSHRC5AR1HSD11B1
SCHEMBL5135729 0.91 PPARG (0.40) PPARGPPARATSHRC5AR1CYP2C19
SCHEMBL5137361 0.90 PPARG (0.36) PPARGPPARATSHRC5AR1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed